Member Info for EmeraldCarrots

Where we are.

So the Directors really think we will get orders from the EU! LOL! CE certification for both machines. Enourmous market. 15,000 hospitals in the EU! If only 1 in 50 buy both machines that's 600 machines and 300 sites for starters.

Seems the way to go. If they could get that cleared for medical use it would be worth hundreds of millions IMHO.

Why don't they do that? They have the illumina assay panel already.

It can catch live, intact circulating tumour cells including clusters. Plus, they are uncontaminated so are ideal for analysis which includes protein expression, RNA and DNA. This machine should be selling like hot cakes. Either it's too expensive or there is some issue I certainly don't know about. So, it must be the costs or some sort of ease-of-use issue? Having said that I have done umpteen hours of research and only found it is an excellent machine and does what it says. My best guess it's either cost, or a monumental sales force failure. Both of these can be addressed.

All issues can be resolved with senior management changes.

All IMHO.

Analysis for the likes of Illumina, Grail, or anyone else. They have the expensive machines and the qualified professional staff. This could suppliment income while dual analysis and the other services they offer are offered. IMHO a major investor should be interested at these ludicrous sp levels. It's truly insane.

All IMHO.

Investing1234.

"Hi, First time I've posted here, I work in the city and I know numerous asset managers have been into see the management trying to get them to commercialize the tech which by all accounts is excellent, sadly the board are more interested in writing obscure white papers that ten people on the planet will read. I held years ago and sold but saw it went down to 7p which I thought looked pretty cheap put a few quid in and we are where we are. Very sad really a business who could have been a game changer but may well get scooped up for scraps when they run out of cash. Guess the adage is follow good management not good tech.".

===================================

Good post. Luckily management can be replaced. The sales side of Angle simply has not managed to deliver and Mr Newland seems to be heavily involved, as the Chief Commercial Officer Brett Swansiger must be too. They both need to step aside IMHO.

All IMHO.

To Parsortix and leave the sales side to someone new. Brett Swansiger has been there for over 2 years as Chief Commercial Officer so his position seems fragile to say the least. I sit here knowing Angle DO really have a lot going for them. The senior management simply have not "delivered the goods". It's not as if Parsortix in not World class, or potentially dual analysis in time can't be the standard test everyone who has suspected cancer is given. I don't see why not. In that case dual analysis may be worth hundreds of millions. Really.

All IMHO.

wonders quote what he says and does. maybe a swift kick in the nuts followed by ***** off, get out now, maybe? lol!

From A.I.:-

Certain situations may exempt you from the notification requirement:

Specific Financial Instruments: Some financial instruments may not trigger a notification, especially if they don't grant voting rights directly or if they are held under specific conditions *****(e.g., some stock lending arrangements). *****. There u go.

Group Structures: As mentioned, parent companies may have a consolidated notification obligation, potentially reducing the need for individual subsidiaries to notify.

Acting as a Custodian: If you are acting as a custodian and only able to vote upon instructions from another party, you may not need to notify.

Conditional Contracts: If the conditions for acquiring voting rights are outside of your control, notification may not be required.

===============================

Biblical proportions might happen. Fingers crossed. They have been talking to both Illumina and Roche. I hope AN is not involved as I suspect he is to do with why Angle can't do the big deals. In fact he must be involved and his track record is appauling. If he leaves maybe the sp will go up!

All IMHO.

I speculate some of the big holders have lent their shares out to Co's that use them to short the stock. Thus technically they have not sold, and so no RNS required. But they get paid when the sp goes down. If so they expect at some point a massive rise. If your in for the long term you can make money if the shares go up or down.

All IMHO.

Why are they advertising these vacancies? Has AN lost the plot?

Manufacturing Laboratory Technician

Product Sales Manager

R&D Verification and Validation Specialist

Sales & Corporate Support Administrator

Clinical Scientist I Molecular

Scientist I Molecular

Senior Clinical Scientist – Molecular

And a sales team that can't sell it. Oppertunity to replace said team, invest in dual analysis and make hundreds of millions.

All IMHO.

Boing.

Is for some reason Astrazeneca have not, so far, asked them to use either of the two CTC analysis assays (Angle developed for them) in any of their cancer drug trials. Also no additional assay orders either from Astra or anyone else recently. I find this very strange. Angle's inability to land orders points to a senior management issue I think. Clearly they have a sellable, indeed excellent product in Parsortix. Also they offer services that simply must be in demand. Dual analysis, that has been backed by Ilumina may make tens if not hundreds of millions in time.

All IMHO.

One might ask why this was even nececessary, could be viewed as yet another complete waste of NHS money. Probably is, and it's several weeks late of course, why is no-one surprised? The machine is no more complicated than the covid test kits millions of people used a few years back. What a joke. I think the UK Government should create yet another commitee to see if NICE etc. should be scrapped. Hasten to add a commiteen of say 13 hightly respected people.

20 mins, 30 secs into preseantation. "The conclusion should be, should be, around about now". NHSE pilot aimed at logistics of CYP2C19 implementation.

https://www.youtube.com/watch?v=MrfHKoBtmPM

https://www.nw-gmsa.nhs.uk/media-news-and-events/case-studies

The project is led by Dr Videha Sharma (Clinical Innovation Lead) and Emma Parnell (Design for Joy), and will follow an design-led approach, meaning it will gather feedback and make. Has anyone emailed these people to ask?

Very overdue now. Hmmm.

Https://www.news-medical.net/news/20250708/Landmark-discovery-reshapes-understanding-of-key-cancer-protein-MCL-1.aspx

Google

"Angle plc MCL-1"

AI Overview

ANGLE plc is a liquid biopsy company that utilizes its Parsortix system to capture and analyze circulating tumor cells (CTCs) for cancer research and clinical applications. MCL-1, in this context, refers to myeloid cell leukemia 1, a protein involved in cell survival and apoptosis. ANGLE plc's PD-L1 service, which utilizes CTCs, has the potential to optimize cancer therapy trials by providing insights into therapeutic response and patient selection.

Here's a more detailed breakdown:

ANGLE plc and Parsortix:

MCL-1 and its relevance:

MCL-1 is a protein that plays a crucial role in regulating cell survival and apoptosis (programmed cell death).

In cancer, MCL-1 can be overexpressed, contributing to cancer cell survival and resistance to therapy.

Targeting MCL-1 with inhibitors is being explored as a potential therapeutic strategy in cancer treatment.

ANGLE's MCL-1 related applications:

PD-L1 Service:

ANGLE offers a PD-L1 service that leverages CTCs for understanding and optimizing cancer therapy. This service can identify and enumerate CTCs, and assess their PD-L1 status, potentially aiding in patient selection for targeted therapies.

Downstream Analysis:

The Parsortix system isolates CTCs, which can then be subjected to various downstream analyses, including assessing MCL-1 expression and other biomarkers.

Research and Drug Development:

ANGLE's technology is used in cancer research, drug development, and clinical oncology to provide insights into cancer biology and treatment response.

In essence, MCL-1 is a relevant target in cancer research, and ANGLE's technology, particularly its CTC capture and analysis capabilities, can be used to study MCL-1 and its role in cancer development and treatment response.

Sharma or Emma Parnell to find out why it is several weeks overdue?

"Overview of the Clopidogrel Pilot Project: CYP2C19 genetic testing for stroke and TIA patients"

The project is led by Dr Videha Sharma (Clinical Innovation Lead) and Emma Parnell (Design for Joy), and will follow an design-led approach, meaning it will gather feedback and make. Has anyone emailed these people to ask?

https://www.nw-gmsa.nhs.uk/media-news-and-events/case-studies